Here are the latest stories being discussed in biopharma today:
Sanofi CEO Discusses Future Plans in Latest Q&A
Sanofi’s CEO, Paul Hudson, recently discussed the company’s future plans in a Q&A. Hudson addressed the company’s interest in using artificial intelligence (AI) across its business. Particularly in areas outside the lab, AI could allow employees to concentrate on meaningful work. He also touched on plans to divest Sanofi’s consumer unit and hinted at developments in the company’s early pipeline.
Akero FGF21 Analog Shows More Positive MASH Data
Akero Therapeutics is back with additional data supporting the effectiveness of its FGF21 analog in metabolic dysfunction-associated steatohepatitis (MASH). The company reported further positive Phase IIb data, showing an improved histology status from week 24 to week 96 in MASH patients treated with the drug candidate, efruxifermin. Akero’s stock saw a noticeable increase following the announcement.
Merck KGaA and C4 Strike $16M Molecular Glue Deal
Merck KGaA recently bagged a molecular glue deal with C4 for an upfront payment of $16 million. The partnership signals a continued interest in the promising field of targeted protein degradation.
Cormorant Nears Close of Fifth Private Healthcare Fund
Private equity firm Cormorant is drawing close to finalizing its fifth private healthcare fund as the biotech sector continues to attract increased investment.
Bayer Acquires European Rights to BridgeBio’s ATTR-CM Pill
Bayer has purchased the European rights to BridgeBio’s ATTR-CM pill in an optimistic move for the pharmaceutical giant.
Pfizer Unveils Ambitious Vision for Cancer Portfolio
Pfizer has shared its ambitious vision for its cancer portfolio as part of a strategy to revitalize its business. The announcement suggests a significant focus on oncology in the company’s future development.
Nocion Raises $62M for Chronic Cough Treatment
Nocion has raised $62 million to develop an innovative approach to chronic cough treatment. The method under development contrasts current methods used by competitors such as Merck and GSK.
Ally Bridge Invests in ‘new generation’ to Celebrate 10-year Mark
Investment firm Ally Bridge marks its ten-year anniversary with significant investments in ‘new generation’ healthcare technologies and resources. The firm looks forward to the next decade of healthcare innovation.
